“The death of this patient was deemed unrelated to treatment with Elevidys,” the company said, citing a report on Bloomberg News. Sarepta (NASDAQ:SRPT) added that its Swiss partner Roche (OTCQX:RHHBY), which markets Elevidys outside the U.S., has also declared that the death was not related to Elevidys.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.